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Background
Programmed cell death-1 (PD-1) is a co-inhibitory
receptor expressed on lymphoid and non-lymphoid-
derived cells that negatively regulates peripheral T-cell
responses. PD-L1, the major PD-1 ligand, is expressed
on various tumors and is being investigated as a possible
predictive marker for anti-PD-1 therapy. Few studies
have determined PD-L1 expression across tumor types
using a consistent process. We evaluated PD-L1 expres-
sion across human tumor samples using a novel, auto-
mated, sensitive, and specific PD-L1 IHC assay (developed
by Dako) using the 28-8 antibody.
Methods
PD-L1 expression in 654 commercially available tumor
samples was explored. Percentage of tumor plasma
membrane staining was determined at ≥1+ intensity.
Macrophage and lymphocyte PD-L1 status was deter-
mined by compartment (tumor, non-tumor associated,
or both). Immune cell density and PD-L1+ immune cell
frequency were assessed on a scale of 0 (none), 1 (mild),
2 (moderate), and 3 (heavy). PD-L1 positivity was evalu-
ated using 5% surface expression values for tumor cell
membrane staining.
Results
Of 654 samples examined, spanning 19 tumors from dif-
ferent sites, 89 (14%) were PD-L1+ (≥5% frequency).
Highest PD-L1+ frequencies were seen in head and neck
(17/54; 31%), cervical (10/34; 29%), cancer of unknown
primary origin (CUP; 8/29; 28%), glioblastoma multiforme
(GBM; 5/20; 25%), bladder (8/37; 21%), esophageal (16/
80; 20%), triple negative (TN) breast (6/33; 18%), and
hepatocarcinoma (6/41; 15%). Across a subset of head
and neck tumor samples, high PD-L1 expression was
seen: lip (2/2; 100%), tongue (2/4; 50%), larynx (11/31;
35%), and oral cavity (2/10; 20%). In breast tumors, TN
tumors showed a higher frequency PD-L1+ status (≥5%
frequency; 6/33 samples [18%]) compared with estrogen
receptor, progesterone receptor, or HER2+ positive
tumors (0/45). PD-L1+ was higher in squamous (SQ)
compared with other histologies within esophageal (SQ
[14/55; 25%] vs other [2/25; 8%]), cervical (SQ [6/15;
40%] vs adenoSQ [2/8; 25%] and adeno [0/5]), and blad-
der (SQ [3/8; 37%] vs transitional [6/27; 22%]) tumors.
PD-L1+ tumors were associated with immune cell density
and PD-L1+ immune cells, especially in TN breast and
laryngeal tumors.
Conclusions
PD-L1 is expressed in various human tumors and is
associated with tumor grade, squamous histology,
immune cell density, and co-localization of PD-L1+
immune cells. Highest PD-L1+ frequencies were seen in
head and neck, cervical, CUP, GBM, bladder, esopha-
geal, TN breast cancer, and hepatocarcinoma.
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